Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) Operating Income

The latest operating income for RVPHW is $-26T as of June 2026. That compares with $-27M in the prior-year period — down 95362271.3% year over year. Investors often review this figure alongside Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, RVPHW's operating income moved from $-27M to $-26T — a 95362271.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s operating scale or balance-sheet position.

A operating income figure of $-26T for RVPHW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RVPHW's operating income ($-26T), review year-over-year change from $-27M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.